Sucampo Receives $15 Million Milestone Payment from Abbott on First Sale of AMITIZA® (lubiprostone) in Japan

  Sucampo Receives $15 Million Milestone Payment from Abbott on First Sale of
  AMITIZA® (lubiprostone) in Japan

AMITIZA is First-ever Approved Prescription Medicine for Chronic Constipation
                                   in Japan

Business Wire

BETHESDA, Md. & TOKYO -- December 11, 2012

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today announced that its
subsidiary, Sucampo AG, has received a $15 million milestone payment from
Abbott’s (NYSE: ABT) subsidiary, Abbott Japan Co., Ltd. (Abbott), pursuant to
the existing license, commercialization, and supply agreement between Sucampo
Pharma Ltd. (SPL), SPI’s subsidiary, and Abbott. The milestone payment was
triggered by the first sale of AMITIZA^® (lubiprostone) capsule 24 μg in
Japan. AMITIZA is available through Abbott in Japan as a prescription
medication for chronic constipation not caused by organic diseases, and was
launched to primary care and specialist physicians on November 21, 2012.

“For years, millions of patients in Japan have been suffering from chronic
constipation,” said Sucampo’s Chairman, Chief Executive Officer, and Chief
Scientific Officer Ryuji Ueno, M.D., Ph.D., Ph.D. “Until the approval of
AMITIZA, there had been no new chemical entity developed for chronic
constipation in Japan in 32 years. Sucampo and Abbott are honored to bring
AMITIZA to the Japanese market, and we look forward to the positive impact we
hope this medicine will have for patients who need it.”

Dr. Ueno also said the availability and first sale of AMITIZA in Japan is
another step forward in the company’s objective of bringing medicines with
novel mechanisms of action to patients globally with unmet medical needs.

AMITIZA is the world’s first chloride channel activator approved for
therapeutic use, and has a unique mechanism of action to restore mucosal
barrier function. With more than six million prescriptions worldwide, it is
the first and currently the only prescription medicine available in Japan for
chronic constipation.

In 2009, SPL and Abbott entered into a license, commercialization and supply
agreement for AMITIZA in Japan.

About Chronic Constipation (excluding constipation caused by organic diseases)

Millions of people in Japan live with the pain and discomfort of chronic
constipation, yet many do not seek physician care. Medical attention could
mean early diagnosis and effective, long-term treatment. More than one-third
of patients in Japan who seek healthcare provider care for constipation are
dissatisfied with their current therapy.


AMITIZA (lubiprostone) is a prostone, a local activator of ClC-2 chloride
channels in cells lining the small intestine. By increasing intestinal fluid
secretion, lubiprostone softens stools and increases motility in the
intestine, thereby facilitating the passage of stool and alleviating symptoms
associated with chronic constipation. Additionally, activation of ClC-2 by
lubiprostone has been shown to stimulate recovery of mucosal barrier function
via the restoration of tight junction protein complexes in ex vivo studies of
ischemic porcine intestine.

Outside Japan, AMITIZA is approved in the United States for the treatment of
chronic idiopathic constipation (CIC) in adults (24 mcg twice daily) and
irritable bowel syndrome with constipation (IBS-C) in women 18 years of age
and older (8 mcg twice daily). AMITIZA is also approved for chronic idiopathic
constipation in Switzerland and the United Kingdom.

AMITIZA is a registered trademark of Sucampo Pharmaceuticals, Inc.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones
was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman,
Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones,
naturally occurring fatty acid metabolites that have emerged as promising
compounds with unique physiological activities, can be targeted for the
treatment of unmet or underserved medical needs. For more information, please

Sucampo Forward-Looking Statements

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
US and internationally, and the exposure to litigation and/or regulatory

No forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Sucampo undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that affect Sucampo's
business, particularly those mentioned in the risk factors and cautionary
statements in Sucampo's Form 10-K for the year ended Dec. 31, 2011, which
Sucampo incorporates by reference.


Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
Press spacebar to pause and continue. Press esc to stop.